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Abstract
Purpose Magnetic resonance-guided laser interstitial thermal therapy (LITT) has been increasingly used to treat a number
of intracranial pathologies, though its use in the posterior fossa has been limited to a few small series. We performed a multiinstitutional review of targets in the posterior fossa, reporting the efficacy and safety profile associated with laser ablation
in this region of the brain.
Methods A retrospective review of patients undergoing LITT in the posterior fossa was performed from August 2010 to
March 2020. Patient demographic information was collected alongside the operative parameters and patient outcomes.
Reported outcomes included local control of the lesion, postoperative complications, hospital length of stay, and steroid
requirements.
Results 58 patients across four institutions underwent LITT in the posterior fossa for 60 tumors. The median pre-ablation
tumor volume was 2.24 cm3. 48 patients (50 tumors) were available for follow-up. An 84% (42/50) overall local control rate
was achieved at 9.5 months median follow up. There were two procedural complications, including insertional hemorrhage
and laser misplacement and 12/58 (21%) patients developed new neurological deficits. There was one procedure related
death. The median length of hospital stay was 1 day, with 20.7% of patients requiring discharge to a rehabilitation facility.
Conclusions LITT is an effective approach for treating pathology in the posterior fossa. The average target size is smaller
than what has been reported in the supratentorial space. Care must be taken to prevent injury to surrounding structures given
the close proximity of critical structures in this region.
Keywords Laser interstitial thermal therapy · Tumor ablation · Posterior fossa
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The posterior fossa presents a unique challenge for neurosurgeons given the anatomic complexity and high eloquence
of tissue confined to this small space. Surgery in this area
carries greater morbidity and mortality compared to its
supratentorial counterpart and is an independent risk factor
for poor clinical outcomes following resection [1–3]. With
risk of postoperative complications such as CSF leak, cranial nerve palsy, and hydrocephalus, surgical resection for
infratentorial lesions presents unique challenges.
Magnetic resonance-guided laser interstitial thermal
therapy (LITT) is a minimally invasive surgical technique
that uses an optical fiber to transmit nonionizing radiation
from a laser source to the target [4]. Its use for primary brain
tumors, radiation necrosis/recurrent metastasis, and pediatric brain tumors is well documented [5–13]. However, the
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literature on laser ablation in the posterior fossa is limited
to a few small case series [14–16]. Establishing the efficacy
and safety profile of LITT in the posterior fossa is crucial
as this treatment modality gains momentum in the field of
neuro-oncology. In this study, we report the largest series to
date of patients who underwent LITT in the posterior fossa
for a variety of oncologic pathologies. We report on local
control, procedural complications, hospital length of stay
(LOS), and pre-/postablation steroid use.

Methods
Patient selection
We retrospectively reviewed patients who underwent LITT
for a posterior fossa neoplasm from October 2010 to March
2020. Patients were evaluated by a multidisciplinary team
to determine their eligibility for laser ablation given their
pathology and treatment history; LITT was considered if
resection posed a high risk, the tumor was surgically inaccessible, or the lesion failed maximal radiation therapy.
All patients were enrolled in an institutional review boardapproved protocol at their respective institution.

Surgical procedure
The procedure for LITT using the Visualase thermal therapy
system (Medtronic Inc., Dublin, Ireland) has been previously
reported [17–19]. Method of insertion was at the discretion

Fig. 1  An Inferior Suboccipital Approach for a Pineal Region Tumor.
Frameless approaches offer a greater flexibility in trajectory implementation compared to frame-based techniques which is critical for
the posterior fossa. Coronal T1-weighted contrast-enhanced MRI
showing a pineal parenchymal tumor of intermediate differentia-
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of the operating surgeon, and all surgeons were experienced
with the technology. Laser insertion was performed via
frameless and framed approaches, with robotic assistance
and with the ClearPoint system (ClearPoint Neuro, Irvine,
California). For the purposes of this study, the decision to
proceed with ablation based on the accuracy of laser insertion was determined by the operating surgeon. Biopsy was
not routinely performed at some institutions during LITT
based on their own institutional protocols. 51/60 laser
placements included in this study were completed using the
Medtronic Vertek Arm and Precision Aiming Device using
a frameless approach [19].
While a number of approaches for laser insertion were
utilized in this study, we have found that some tumors may
be more appropriately treated by a certain technique. In our
experience, frame-based techniques offer exceptional precision, though the bulk introduced by these systems often limits more robust trajectories. The frameless approach allows
for more flexibility in trajectory implementation, especially
for more inferior trajectories (Fig. 1). Beyond the decision of
which targeting system to use, trajectory planning involves
a thorough evaluation of the anatomy. This will allow for
more effective targeting of brainstem tumors (Fig. 2) and
enable the operator to bypass traditional anatomic boundaries (Fig. 3).

Data collection
Demographic information, pathology, tumor location, presenting problem, preoperative symptoms, and operative

tion (left) in the pineal region and an inferior suboccipital trajectory
(right) with insertional hemorrhage (arrow). A frameless approach
enabled a sufficiently inferior trajectory for laser insertion across the
long axis of the tumor which likely would not have been possible
with a frame-based technique
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Fig. 2  A Comparison Between a Frontal and Transcerebellar Trajectory for Pontine Tumors. Pontine tumors can typically be approached
by either a frontal or transcerebellar trajectory, with the decision in
which trajectory to use dictated by the morphology of the tumor.
Axial T1-weighted MRI with gadolinium (a) showing tumor local-

ized to the right pons. Trajectory implementation involved utilizing a frontal approach to the pons through the midbrain (b). Axial
T1-weighted image (c) shows an anterior pontine tumor in another
patient to demonstrate an alternative transcerebellar approach (d)

variables were gathered from hospital charts. The presenting problem was considered the primary reason the patient
presented (i.e. the predominating symptom or radiographic
progression via serial imaging), whereas preoperative symptoms incorporated all of the patient’s reported symptoms.
Infield recurrence was considered to be recurrence within a
previously radiated field following stereotactic radiosurgery
for a metastatic tumor; it may represent radiation necrosis,
recurrent metastasis, or both [6, 10, 20].
End points included local control, postoperative complications, hospital LOS, 30-day readmission rate, and steroid use. Hospital LOS was defined as the amount of days
spent in the hospital post-ablation, since some patients

were admitted the day before the procedure for preoperative imaging. The 30-day readmission rate was measured by
identifying readmissions directly related to LITT. Postoperative complications were defined as inpatient events only.
Any resolution in new neurological deficits was assessed
through outpatient records. Local control was defined as lack
of tumor progression after LITT. Progression was defined as
enhancement that increased in size by a minimum of 25%
in two dimensions on two consecutive MRI scans (contrastenhanced T1) 4–12 weeks apart, or enhancement accompanied by symptoms necessitating intervention. Long-term
steroid use was considered to be dexamethasone use beyond
the postoperative taper (typically a 1–2 week taper).
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Fig. 3  Transoccipital Transtentorial Stereotactic Laser Ablation of
Cerebellar Vermian Metastatic Tumor. Traditional anatomic boundaries such as the tentorium can be traversed if the morphology of the
tumor demands a transtentorial approach. Shown is the preoperative
gadolinium-enhanced axial T1 image (a) and preoperative axial T2
image (b). Preoperative stereotactic trajectory view (c) demonstrates
a transtentorial approach which would allow adequate ablation of the

tumor, and intraoperative direct MRI guidance view shows transtentorial placement (d) of the laser apparatus. E Immediate post-treatment
effects visualized with axial T2 image. F 6-week postoperative gadolinium-enhanced axial T1 image showing treatment effects without
progression of lesion. G 6-week postoperative axial T2 image showing treatment effects with decreased edema and mass effect

Imaging protocol and analysis

was carried out with OsiriX MD (Pixmeo SARL, Geneva,
Switzerland) [21].

Exact institutional imaging protocols varied, but each center
obtained at least two MRIs during each hospitalization:
within 24 hr pre-operatively and within 24 h after LITT.
After discharge, patients obtained sequential MRIs every
4–12 weeks, though this interval was increased in the cases
of exceptional long-term control following laser ablation.
The extent of ablation was quantified by calculating the 24-h
postablation-to-preablation tumor volume ratio; this ratio
was used to assess the effect that extent of ablation has on
local control and the development of postoperative neurological deficits. Tumor dimensional and volumetric analysis

13

Statistical analysis
Statistical analyses were done using Prism 8.2.1 (GraphPad Software, La Jolla, California). Categorical data are
reported as percentages, and continuous data are presented
as the mean with standard error of the means. Comparisons in demographics, operative parameters, and outcomes
between cerebellar and brainstem lesions were considered
separately; outcomes were also compared between patients
with primary and secondary brain tumors. Differences are
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considered significant with p < 0.05. Statistical analysis
was completed via Student’s t-test for continuous data and
Fisher’s exact tests for categorical data.

Results
Patient demographics
A total of 58 patients with 60 tumors underwent LITT in
the posterior fossa. Patient demographics, tumor pathology, and operative parameters are summarized in Table 1.

There were a total of 15 primary tumors and 45 secondary
tumors (44 cases of infield recurrence and one untreated
metastatic tumor). Of the patients with infield recurrence,
primary tumor pathology included breast cancer (n = 18),
non-small-cell lung cancer (n = 16), melanoma (n = 4),
neuroendocrine tumor, cholangiocarcinoma, small-cell
lung cancer, renal cell carcinoma, ovarian cancer, and cervical cancer (n = 1 each). Preoperative symptoms among
all patients, beyond the presenting complaint, included
balance difficulty (n = 14), headache (n = 13), motor weakness (n = 7), dizziness (n = 3), vision problems (n = 3),

Table 1  Patient demographics information, operative parameters, and ablation volumes
Total

Number of tumors
Sex (n, %)
Male
Female
Age (range)
Pathology (n, %)
Infield recurrence of a previously radiated
metastatic tumor
Glioblastoma
Pilocytic astrocytoma
Low grade glioma
Hemangioblastoma
Anaplastic astrocytoma
Ependymoma
PPTID
Untreated metastatic tumor
(breast)
Presenting problem (n, %)
Radiographic progression
Balance difficulty
Headache
Motor weakness
Sensory deficit
Nausea
Operative parameters
Preoperative target volume (cm3)
Laser power (Watts)
Ablation time (Seconds)
Number of ablations
Trajectory length* (mm)
24-hour postablation volume ( cm3)
Postablation-to-preablation volume ratio

Location
Brainstem

Cerebellum

Pineal region

60

7

52

1

18 (31%)
40 (69%)
56.4 ± 2.2
[4-90]

5
2
46.0 ± 9.7 [4-75]

12
38
58.0 ± 2.2 [23-90]

1
0
51

44 (73.3%)

2

42

0

4 (6.7%)
3 (5%)
2 (3.3%)
2 (3.3%)
2 (3.3%)
1 (1.7%)
1 (1.7%)
1 (1.7%)

4
0
0
0
0
1
0
0

0
3
2
2
2
0
0
1

0
0
0
0
0
0
1
0

34 (58.6%)
9 (15.5%)
9 (15.5%)
3 (5.2%)
2 (3.4%)
1 (1.7%)

0
2
0
3
2
0

34
6
9
0
0
1

0
1
0
0
0
0

2.24 ± 0.21
9.93 ± .0.26
404.3 ± 44.6
2.94 ± 0.27
70.3 ± 3.9
3.92 ± 0.28
2.38 ± 0.28

3.24 ± 0.59
9.3 ± 0.56
406.7 ± 87.1
3.57 ± 0.72
123.3 ± 6.5*
3.73 ± 0.63
1.17 ± 0.08

2.11 ± 0.22
10.0 ± 0.3
400.1 ± 51.0
2.74 ± 0.29
61.9 ± 3.1*
3.97 ± 0.31
2.57 ± 0.32

2.32
10.4
570
4
110.8
2.81
1.21

PPTID pineal parenchymal tumor of intermediate differentiation
*Reached statistical significance (p < 0.05)
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sensory deficit (n = 2), nausea (n = 2), hearing difficulty,
and cognitive decline (n = 1 each).
53 patients (91%) had undergone prior intervention for
their tumor. Patients with primary tumors previously underwent craniotomy (n = 6), radiotherapy (n = 1), or both craniotomy and radiotherapy (n = 3). Secondary brain tumors
were previously treated by stereotactic radiosurgery (n = 34)
or both craniotomy and stereotactic radiosurgery (n = 9).
Among the patients who had not received prior intervention, primary pathology was glioblastoma (n = 2), hemangioblastoma, pilocytic astrocytoma, and metastatic breast
cancer (n = 1 each).

Local control
Ten patients did not have follow-up records for the subsequent reasons: one patient had the procedure aborted following improper placement of the laser and underwent subsequent resection; five patients continued care at outside
hospitals; two patients died prior to follow-up (one patient
died secondary to procedural complications and another
patient with primary NSCLC died due to pneumonia); two
patients were placed on hospice care due to extracranial
disease progression. The remaining 48 patients (50 tumors)
were available for clinical and radiographic follow up.
The median duration of follow-up was 9.5 months (range
0.6–81.5) for 48 patients. LITT resulted in an overall local
control rate of 84.0% (42/50). Stratifying patients by tumor
location revealed a local control rate of 50.0% (2/4) for
brainstem tumors and 87.0% (40/46) for cerebellar locations
(p = 0.115). Primary and secondary brain tumors demonstrated local control rates of 60% (6/10) and 90.0% (36/40),
respectively (p = 0.0407). The 24-h postablation-to-preablation volume ratio was lower in patients with recurrence
than in those without recurrence (1.67 ± 0.26 vs 2.54 ± 0.36,
p = 0.3057). The median time from laser ablation to recurrence was 5.5 months (range 2.8–14.6). Five patients with
recurrence pursued further treatment: two patients underwent craniotomy, one patient opted for radiosurgery, and two
patients had changes made to their chemotherapy regimen.
Local control among patients with infield recurrence was
89.7% (35/39). Biopsy was employed in 13 of these cases,
revealing recurrent metastasis in seven cases, radiation
necrosis in four cases, and mixed recurrent tumor and radiation necrosis in two cases; local control was 100% for each
of these histopathologic diagnoses at median follow-ups of
11.5 months (recurrent metastasis), 9.6 months (radiation
necrosis), and 7.6 months (mixed tumor/radiation necrosis).

Procedural complications
There was a total of 14 complications in this study (24.1%),
consisting of two procedural complications and new
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neurological deficits in 12 patients (Table 2). 57% (4/7) of
patients with brainstem tumors developed complications
whereas ablation within cerebellum led to a 20% complication rate (p = 0.0541). Evaluation by tumor type revealed
complication rates of 43% (4/14) and 18% (8/44) in patients
with primary and secondary brain tumors, respectively
(p = 0.0791). Of these 12 patients with new deficits, five
had a persistent deficit at last follow-up, four showed partial
resolution, two had complete resolution, and one was placed
on hospice.
Catheter misplacement occurred in a patient who had
LITT for a cerebellar hemangioblastoma. Imaging confirmed
the catheter was inserted superior to the target, and the
patient then opted for resection. Another patient was noted
to have a superficial insertional hemorrhage which required
evacuation following ablation. There was one procedurerelated mortality in this cohort. The patient had LITT for a
midbrain glioblastoma, and subsequently died 8 weeks later
secondary to refractory edema.
The 24-h postablation-to-preablation tumor volume
ratio was compared between patients with and without new
postoperative neurological deficits. Interestingly, patients
that developed postoperative complications had a lower
postablation-to-preablation tumor volume ratio compared to
patients without deficits, though this difference was not statistically significant (1.34 ± 0.09 vs 2.66 ± 0.35, respectively;
p = 0.0502). There was no association between the development of complications and catheter insertion approach
(p = 0.6786) or pre-ablation tumor volume (p = 0.6445).

Hospital stay and readmissions
The mean hospital LOS was 2.50 ± 0.42 days (range 1–22,
median 1). Analysis by target location revealed those with
ablation in the brainstem had a mean LOS of 5.5 ± 2.52 days
(range 1–22, median 2), which was longer than patients with
cerebellar ablation who had a mean LOS of 2.0 ± 0.24 days
(range 1–8, median 1) (p = 0.0416). Patients with complications had higher LOS than those without, with an average stay of 4.79 ± 1.42 days compared to 1.75 ± 0.25 days,
respectively (p = 0.0013). At the time of discharge, 12
patients (20.7%) were sent to a rehabilitation facility, and
46 patients were sent home (79.3%). The 30-day readmission rate was 0%.

Steroid use
18 of the 48 patients (37.5%) in this study with long-term
follow-up were taking steroids preoperatively. Post-procedurally, 46 patients (95.8%) were placed on 1 to 2-weeks
steroid tapers. Among the patients that had been on steroids
pre-operatively, 50% achieved steroid freedom on followup. 9/30 (30%) patients that had not been taking steroids
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Table 2  Postprocedural neurological deficits
Degree of resolution of new neurological deficit

Target location

Pathology

Pre-ablation
lesion volume
(cm3)

Neurological
deficit following
ablation

Right midbrain

Glioblastoma

6.20

Right pons

Infield recurrence

1.91

Right cerebellar
peduncle

Infield recurrence

1.01

Right cerebellopontine angle
Right midbrain

Pilocytic astrocytoma
Glioblastoma

0.69

Refractory cerebral Persistent
edema
Hemiparesis
N/A, patient
placed on hospice
Facial nerve palsy Persistent
(House-Brackmann V)
Hearing loss
Persistent

3.70

Anterior pons

Infield recurrence

1.86

Right cerebellum
Left cerebellar
peduncle
Right cerebellar
peduncle
Cerebellar vermis
(2 targets)

Infield recurrence
Pilocytic astrocytoma
Infield recurrence

1.68
3.56

Anaplastic astrocy- 1.51, 2.47
toma

Left cerebellum
Left cerebellum

Infield recurrence
Infield recurrence

1.90

3.35
1.83

Facial droop and
hemiparesis
Facial droop and
hemiparesis
Arm weakness
Hearing loss
Dysmetria and
slurred speech
Truncal ataxia and
scanning speech

Discussion
As more neurosurgeons incorporate LITT into their practice,
elucidating the capabilities and limitations of this technology is critical for optimizing the treatment of intracranial
tumors. To that end, we present a multi-institutional series
of patients that underwent LITT for a number of oncologic
pathologies within the posterior fossa.
Local control rate was 84% with a median follow-up
of 9.5 months, consistent with another study published
by Borghei-Razavi et al. [14] They presented a series of 8
patients who underwent LITT for infratentorial metastases,
radiation necrosis, pilocytic astrocytomas, and glioblastoma with a local control rate of 75%. In addition, Dadey

Post-ablation steroid
course

2 mg twice daily

2 mg twice daily
until death
2-week taper to off

4 mg twice daily
4 mg four times
daily

4 mg twice daily

None

2-week taper to off

Partial

None

1 mg daily

Persistent

None

Partial
Persistent

1 mg twice daily
None

4 mg four times
daily
1 mg twice daily
1-week taper to off

Partial

None

Partial

2 mg twice daily

Diplopia
Complete
Speech impairment Complete
and balance difficulty

preoperatively required long-term steroids, typically due to
persistence of symptomology. There was no significant difference between these two groups (p = 0.222).
When looking at each subset of patients, there was no
significant difference in preoperative and long-term postoperative steroid use in patients with brainstem and cerebellar
lesions (p = 0.486 and p = 0.825, respectively).

Pre-ablation steroid dose

None
3 mg once daily

6 mg four times
daily
4 mg four times
daily for
11 months
2-week taper to off
2 mg once daily

et al. [15] published a series of five patients, two of which
underwent LITT in the posterior fossa for gangliogliomas;
neither experienced recurrence. Both of these studies are in
contrast to the findings presented by Traylor et al. [16] who
investigated the use of LITT infratentorially for five cases
of radiation necrosis and eight cases of metastases. Overall,
there was recurrence in 69.2% of the subjects. While this
recurrence rate is higher than the studies previously discussed, there is notable heterogeneity between these studies
in terms of the specific tumor pathologies treated. Overall,
more research is needed to investigate the efficacy of LITT
for specific tumor pathologies. Furthermore, control rates
are much more a function of the underlying histopathology
than the specific location.
Postoperative complications secondary to LITT can be
categorized as either secondary to thermal ablation (due
to hyperthermia, post-ablation edema, or ablation-induced
hemorrhage) or laser insertion [4, 6, 9]. In this study, we
encountered a complication rate of 24.1%. Two complications were secondary to laser insertion, specifically insertional hemorrhage and catheter misplacement; neither
patient had lasting effects from these complications. The
remaining 12 complications were related to thermal ablation
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resulting in new neurological deficits, of which 5 patients
had persistent deficits at last follow-up. The one procedurerelated mortality occurred in a patient with a 6.2cm3 midbrain glioblastoma, preoperatively putting him at high-risk
for ablation-related complications. Three prior studies evaluating LITT in the posterior fossa with 5, 8, and 13 patients
reported complication rates of 0%, 37.5%, and 7.7%, respectively [14–16]. While our results fall within this range, it is
difficult to draw any definitive conclusions given the high
variability and small sample size in these reported cases.
Upon risk-stratifying patients before intervention, we
have found that patients with symptomatic improvement
with steroids preoperatively typically do not develop complications following ablation, as their initial symptomology was likely due to edema as opposed to infiltration. The
compactness of the gray and white matter in the posterior
fossa indicates that the sensitivity of target location is more
critical than the volume. Several patients that developed permanent deficits despite low volume ablation had involvement of facial and motor tracts in close proximity to the
target. 4/12 patients with new deficits had brainstem tumors.
Overall these findings serve to illustrate the higher risk associated with LITT in the brainstem and closer to the midline
in the posterior fossa. The volumetric analysis did show
that the majority of tumors in the posterior fossa that underwent LITT were smaller (< 4cm3) than those targeted in the
supratentorial space, emphasizing the lower volume threshold for treatment of infratentorial targets.
Assessing the ability of LITT to reduce rates of steroid
dependence is an important component of its overall efficacy given the consequences of long-term dexamethasone
treatment [22]. Of the patients on steroids preoperatively,
50% were successfully weaned off dexamethasone following
LITT. However, 30% of patients that did not require preoperative steroids had been on steroids at last follow-up. This
highlights the utility of LITT in helping patients achieve
steroid freedom, though also suggests that it may not prevent
long-term steroid use among patients that did not require
them preoperatively.
LITT has been shown to have a shorter hospital LOS
when compared to surgical resection [9, 23], and this holds
true for patients undergoing thermal ablation in the posterior fossa. Our findings show a median LOS of 1 day, with
previous series demonstrating a similar trend [14–16]. This
is in contrast to patients with infratentorial tumors who are
treated with resection, in which one study with 152 patients
reported a median LOS of 7 days [24]. Moreover, there were
no reported complications of CSF leak or infection in this
series, a notable advantage over resection in the posterior
fossa [1].
While the majority of patients presented in this study
underwent bone-fiducial-based frameless stereotaxy,
individual surgeons also chose to utilize frame-based
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approaches, the Clearpoint system, and stereotactic robot
assistance with good results. Dadey et al. [15] presented a
series of five patients which underwent LITT in the posterior
fossa using the NeuroBlate system (Monteris Medical, Plymouth, Minnesota). They utilized the StarFix microTargeting
platform (FHC, Bowdoin, Maine), a platform-based stereotactic approach which uses a customized frame to guide the
laser catheter. They noted exceptional accuracy of the trajectory without a significant learning curve in implementing the
technology. Similarly, Borghei-Razavi and colleagues [14]
used the StarFix platform in a cohort of eight patients and
did not report any issues with trajectory planning. Careful
attention should be paid to the advantages and limitations
of each approach to maximize ablation for each individual
patient.
This study has several limitations. Ten patients (ten
tumors, 17.2%) that underwent ablation were unavailable for
follow-up, potentially introducing a source of survivorship
bias and affecting the local control rate and steroid requirement analysis. Furthermore, our series featured nine different tumor pathologies split between 58 patients. While this
illustrates the potential wide breadth of LITT, it lacks the
power to adequately demonstrate the efficacy or safety profile of laser ablation for any single diagnosis. Our cohort also
had a preponderance of secondary brain malignancies, making our results less generalizable to primary tumor pathologies. The majority of patients treated for infield recurrence
did not undergo a biopsy due to certain institutional care
algorithms in which biopsy would not change the treatment
plan [6]. While this potentially limits the understanding of
the underlying pathology, the overall control rate in this
series exceeds 80% when considered in aggregate. This is a
result of institutional heterogeneity in how the procedure is
performed and could potentially be solved in the context of a
prospective trial. In addition, this study employed a number
of LITT targeting techniques. This demonstrates the feasibility of each system for infratentorial LITT, but the small
number of cases with some systems precluded a detailed
analysis of how certain approaches may be associated with
target location and trajectory planning.

Conclusions
This multi-institutional study demonstrates the efficacy and
safety of LITT as a treatment modality for posterior fossa
neoplasms, particularly secondary tumors. Care must be
taken to prevent damage to surrounding neural structures
as long-term neurological morbidity and death may occur,
especially for targets in the brainstem. Proper patient selection, coupled with careful trajectory planning, is essential to
preventing complications while maximizing thermal ablation, thereby allowing long-term tumor control. While this
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work provides a deep look into the capabilities of LITT in
targeting infratentorial lesions, larger studies are necessary
to assess its efficacy amongst different tumor pathologies
and its safety profile within subregions of the posterior fossa.
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